Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood
Status:
Completed
Trial end date:
2019-09-27
Target enrollment:
Participant gender:
Summary
The objective of this study is to test the hypothesis that liraglutide (commonly known as
Victoza) can promote an anti-inflammatory macrophage phenotype in human adipose tissue and
blood, thereby reducing localized and systemic inflammation which are risk factors for
cardiovascular disease and may contribute to hyperglycemia. This will be done after 4 weeks
of treatment during which weight will remain stable, and again after 12 weeks, during which
liraglutide-related weight loss occurs.